Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The most effective method to Shield Your Gold Ventures: Procedures and Precautionary measures - 2Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- 3Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- 4Far-right leader Le Pen to attend Brigitte Bardot's funeral
- 52 new malaria treatments announced as drug resistance grows
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Story of ‘first Black Briton’ rewritten by advances in ancient DNA technology
- US FDA investigates Takeda's blood disorder drug after pediatric death
- SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- Holiday season sees uptick in norovirus cases, according to CDC
- From Representative to Business visionary: Private issue Victories
- Is Chinese food truly flavorful?
- The 10 Most Noteworthy Games in History
